← Omeros Corporation (OMER) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Omeros Corporation (OMER)
Pharmaceutical Preparations · market cap $1.5B · as of 2026-07-21
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-12 (est.)
Earnings
Pipeline
13
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Omeros Corporation (OMER) is a commercial-stage pharmaceutical company with a sprawling pipeline spanning surgical, hematologic, urologic, and psychiatric indications. With cash of only $1.9M and a runway of approximately 0.4 months, the company faces an acute near-term liquidity crisis despite a $701M market cap. The lead asset OMS103HP is in Phase 3 for ACL reconstruction, with a next meaningful readout being a Phase 2 data update for OMS906 in PNH estimated for December 2026.
The catalyst path
- 2026-11-12 (est.)Earningsimp 5/10
- 2026-12-15 (est.)Phase 2 · OMS906 study drugimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| OMS103HP | Phase 3 | Anterior Cruciate Ligament Reconstruction |
| OMS201 | Phase 2 | Urinary Calculi |
| OMS103HP-S | Phase 3 | Meniscal Tear |
| OMS721 | Phase 2 | Thrombotic Microangiopathies |
| OMS906 study drug | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria |
| OMS302 | Phase 3 | Intraocular Lens Replacement |
| OMS302-PE | Phase 2 | Cataract Extraction |
| OMS906 | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria |
| Phenylephrine HCl | Phase 3 | Unilateral Cataract Extraction |
| OMS302 Solution | Phase 2 | Cataract |
| Biological: narsoplimab | Phase 2 | Thrombotic Microangiopathies |
| OMS643762 | Phase 2 | Schizophrenia |
| pioglitazone | Phase 2 | Opioid Abuse |
Price & technical context
3-month
+99.0%
6-month
+52.9%
12-month
+350.5%
52-wk range
$4.10–$21.05
vs 50-day MA
+10.1%
vs 200-day MA
+42.7%
Realized vol
136.0%
Max drawdown
-75.6%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for OMER (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 13 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.